RBC Capital Maintains IGM Biosciences(IGMS.US) With Buy Rating, Maintains Target Price $20

RBC Capital analyst Brian Abrahams maintains $IGM Biosciences(IGMS.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate of 48.5% and

Futu NewsJun 21 00:31 · Ratings

Shareholders May Find It Hard To Justify Increasing IGM Biosciences, Inc.'s (NASDAQ:IGMS) CEO Compensation For Now

Yahoo FinanceJun 5 19:26

Will IGM Biosciences (NASDAQ:IGMS) Spend Its Cash Wisely?

Simply Wall StJun 4 22:44

IGM Biosciences to Present at the Jefferies Healthcare Conference

GlobeNewswireMay 29 19:00

In-Depth Examination Of 6 Analyst Recommendations For IGM Biosciences

BenzingaMay 24 22:00

H.C. Wainwright Maintains IGM Biosciences(IGMS.US) With Hold Rating, Maintains Target Price $12

H.C. Wainwright analyst Robert Burns maintains $IGM Biosciences(IGMS.US)$ with a hold rating, and maintains the target price at $12.According to TipRanks data, the analyst has a success rate of 23.4%

Futu NewsMay 24 18:32